Rezultati pretraživanja
  1. prije 1 sat

    Good news! The ACR/ARP highlights are now available in Chinese 🇨🇳 and Japanese 🇯🇵 languages ➡️ Get the most out of !

  2. new Guidelines OA: 🥊exercise (aerobic/streng/neuroM/aquatic🏖) 🥝🥬🔽weigth🚫🍔🚫 ✅tai chi 🚫TENS🚫(no evidence) ✅topical/oral NDSAIDs/intraarticular GCs 🚫intraarticular HyA (hip)🚫 🚫glucosamine and/or chondroitin🚫 (Look slides 👁👁)

  3. 21. stu 2019.

    "Update in Myositis" session with tips on how to use the new classification criteria I honestly find them difficult and only reference in marginal cases Excellent tables from the presentation, though - great reference for antibodies and presentations!

  4. 22. stu 2019.

    - Update in Myositis: Don't forget about toxin induced myopathy! Important mimickers related to treatment we give! 1. Steroid: myopathy w/o inflammation 2. Colchicine: vacuolar myopathy 3. Anti-malarial: vacuolar degeneration P.S. This might be good boards prep...

  5. 16. stu 2019.

    Presenting our poster "Antisynthetase Syndromes: Correlation of IIFA Patterns with Diagnosis Criteria Fulfillment" at in Atlanta. Many thanks to , and for contributing to this project and its presentation at this meeting.

  6. 24. stu 2019.

    Excited to share this report of the big takeaways for patients, with lots of help from & others. Too much to pack into just one resource, so we have 6 wrap-up stories this year!

  7. We’ve got another special Hot Topics episode available on the podcast! Join our host Dr. Hausmann, along with Dr. Ali Duarte Garcia and Dr. Suleman Bhana, as they discuss studies featured in press conferences.

  8. Multiple SS-clinical trial results presented at . The challenge to identify responders remains! Lots of interest for our abatacept follow-up data (week 48) presented by Jolien!

  9. Listen in for insights and highlights discussed during the podcast from the American College of Rheumatology 2019 conference, : Hear the results of the next promising and new treatments in and

  10. 1. velj

    Rt : Episode 7 of ACR on Air looks at a few more studies featured during our press conferences. Listen at:

  11. 16. pro 2019.

    Retrospective cohort study of 154 RA patients undergoing 244 major surgeries in shows that perioperative use of DMARDs (39%) or biologics (13%) was not associated with 30-day odds of post-operative infection Abst #1805

  12. Prikaži ovu nit
  13. 2. pro 2019.

    Management of GCA Guidelines from (FIXED!): The presenter went quickly by the slide on methotrexate & the slide deck was not available during the presentation. Small update now that slides are available, MTX recs included: "[MTX] can be considered as initial treatment"

  14. 24. stu 2019.

    This is the best summary of that I’ve seen. Great work putting this together and the rest of the community.

  15. 23. stu 2019.

    I missed this one during (found via 's weekly roundup): Abstract L19: Early study, but BAFF inhibitor Ianalumab met its primary endpoint in primary Sjogren's.

  16. spent several days in atlanta w/ my friends & colleagues & . it’s taken many years of advocacy to reach this moment. thank you for inviting patient advocates in such a meaningful way to author abstracts & present posters at

  17. 18. stu 2019.

    I wrote about being a first time patient at . What an amazing experience, I WILL go again! Thank you for sponsoring me! Thank you for being my mentor. Also thanks to those who came to see me speak!

  18. 15. stu 2019.

    This is exiting progress for patient inclusion. let's continue to advance patient perspectives in research . Patient partners from Canada & US, I invite you to do Patient Engagement In Research Scale (PEIRS) online survey.

  19. 15. stu 2019.

    The gist: blood levels and thrombotic events in . Risk reduction may be 2-3 times higher than for aspirin in secondary prevention of vascular events. Need to define treat to target strategies.

  20. 14. stu 2019.

    ❓Can the happiest subspecialists experience burnout? 🌻 Now back from , I am rekindled with a new spark and inspiration thanks to each and every one of you! ⬇️ Please read my article for on burnout in rheumatology:

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.